Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats
Introduction
Portal hypertension is one of the more common and severe complications that develop in patients with chronic liver diseases. Development of a hyperdynamic splanchnic circulatory state is a major component of the portal hypertensive syndrome. The increase in blood flow in splanchnic organs draining into the portal vein, and the subsequent increase in portal venous inflow, aggravates and perpetuates the portal hypertensive syndrome, especially when portal-systemic collaterals are extensive [1]. The mechanisms underlying this splanchnic hyperemia are not fully understood, but it has been shown that it is associated with an overproduction of endogenous vasodilators and decreased vascular reactivity to vasoconstrictors [1].
An intriguing possibility is that an increased formation of splanchnic blood vessels through an angiogenic process could also be involved in the maintenance of a hyperdynamic splanchnic circulation in portal hypertension. This hypothesis is based on our recent findings demonstrating the presence of increased splanchnic angiogenesis in a murine model of portal hypertension, and the involvement of this neovascularization on the formation of portal-systemic collateral blood vessels in portal hypertensive animals [2]. In the present study, we determined the hypothesis that hyperdynamic splanchnic circulation in portal hypertension is, at least in part, a vascular endothelial growth factor (VEGF)-dependent angiogenic process by assessing the hemodynamic effects of a specific inhibitor of VEGF receptor-2 in portal hypertensive rats.
Section snippets
Materials
SU5416 was provided by Sugen, Inc. (South San Francisco, California). Rabbit polyclonal antibodies against rat CD31, VEGF receptor-2 and VEGF, as well as the enhanced chemiluminescence western blotting system were from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish peroxidase-conjugated anti-rabbit IgG was from Stressgen (Sidney, Canada). 85Sr-labeled and 51Cr-labeled microspheres were from Perkin-Elmer (Boston, MA). Protein assay kit, and nitrocellulose membranes were from Bio-Rad
Results
SU5416 treatment was well tolerated, and no mortality was observed after daily treatment at 20 mg kg−1 day−1 for 5 days. The average body weight at the time of the studies was similar in the two groups of portal hypertensive rats: 293±19 g in the vehicle group versus 305±10 g in the SU5416 group (P=0.6).
Blockade of VEGFR-2 by SU5416 markedly attenuated the splanchnic hyperdynamic circulation observed in portal hypertensive rats. Thus, portal venous inflow was significantly decreased (by 44%) in PPVL
Discussion
The present study demonstrates that VEGF-dependent angiogenesis markedly contributes to both the development of hyperdynamic splanchnic circulation and the formation of portal-systemic collateral blood vessels, two major components of the portal hypertensive syndrome. Thus, our results show that antagonization of the VEGF/VEGFR-2 signaling pathway, by administration of SU5416 [4], [5], [6], [7], significantly decreased portal venous inflow (44% inhibition), and increased splanchnic arteriolar
Acknowledgements
This work was supported in part by grants from the Ministerio de Ciencia y Tecnologia (SAF2002-01461) and Instituto de Salud Carlos III (PI02739 and CO3/02). M.F. is the recipient of a contract from the Programa Ramon y Cajal, Ministerio de Ciencia y Tecnologia. We thank Dr Carlos Piera and Nieves Campos for technical assistance, Dr Raul Mendez for helpful discussions, and Sugen Inc. for providing the VEGFR-2 inhibitor SU5416.
References (22)
- et al.
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice
Gastroenterology
(2004) - et al.
Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats
Gastroenterology
(1995) - et al.
Inhibition of tumor growth, angiogenesis and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy
Neoplasia
(1999) - et al.
Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition
Gastroenterology
(1992) - et al.
Acute and chronic cyclooxygenase blockade in portal hypertensive rats: influence on nitric oxide biosynthesis
Gastroenterology
(1996) - et al.
Pathophysiology of portal hypertension
Gastroenterol Clin North Am
(1992) - et al.
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
Cancer Res
(1999) - et al.
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
Anticancer Drug Des
(2000) - et al.
Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416
J Pharm Pharmacol
(2001) - et al.
Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamic in rats with long-term bile duct ligation
Hepatology
(1993)